logo
A founder who bet on 350 startups says passing on a hot AI company taught him a hard lesson

A founder who bet on 350 startups says passing on a hot AI company taught him a hard lesson

Immad Akhund, an active angel investor since 2016, passed on an early bet in Scale AI — worth nearly $14 billion in last year's funding round — and it taught him an important lesson.
"I saw Scale AI. And I was like, 'good idea, but these people are so young,'" he said on an episode of the "Twenty Minute VC" podcast published Monday.
"I think they were like 19 and 20 at the time or something. I think I could run this company better if I was doing it and I didn't see how they were going to figure it out," he added.
Looking back, the serial entrepreneur said he was "just so wrong."
"There's some power to that youth that's hard to judge, to be honest. You kind of have to suspend belief and say, okay, this person's going to figure out how to run a huge company," he said.
The misstep was a formative one for Akhund, who has backed more than 350 startups at their earliest stages, including Rappi, Airtable, Rippling, Decagon, and Etched.
Akhund angel invests in "things that will seem inevitable 10 years from now and can be $10 billion companies," he told Business Insider in a May story about the most successful seed-stage investors.
Akhund is also the founder and CEO of Mercury, a banking startup that recently raised a $300 million Series C round at a $3.5 billion valuation led by Sequoia.
Leaving his ego at the door
Akhund said one of the biggest lessons in his investing journey was learning to check his ego.
As an entrepreneur, he was used to suggesting his ideas when speaking with startups, he said.
The founders, especially if they were young, would often concur. But "that's not their idea, and it's not even fair to push an idea on other people," he said.
He learned that it was important to back founders for their ideas, not for his.
"You really have to actually remove your ego and your ideas and really listen," he said. "You're much more along for their journey rather than a major part of it," he added.
Akhund said that he prefers serial founders to first-timers, especially those with "a chip on their shoulder."
"I have such a bias toward them," he said. "A serial entrepreneur knows how hard it's going to be, but they're willing to do it again."
That's "so unusual" and signals that "they must really want to do this," he added.
For investors, Akhund advises making diversified bets.
"Do at least 20 or 30 investments — that's when you start entering the game," he said.
"You learn a lot by doing subsequent ones," he said, adding that investors "need a diversified portfolio to have any return in this space."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Report: Meta is hitting pause on AI hiring after its poaching spree
Report: Meta is hitting pause on AI hiring after its poaching spree

TechCrunch

time5 hours ago

  • TechCrunch

Report: Meta is hitting pause on AI hiring after its poaching spree

In Brief Meta has frozen hiring in its AI organization after restructuring the unit earlier this week, reports The Wall Street Journal. The hiring freeze follows weeks of poaching more than 50 AI researchers and engineers from competitors. The freeze went into effect last week, and it's not clear how long it will last. Meta is still likely working through its reorg, which split its AI unit, Meta Superintelligence Labs, into four new groups: TBD Labs, run by former Scale AI founder Alexandr Wang, and three groups focused on research, product integration, and infrastructure, respectively. Meta confirmed the hiring freeze with The Journal, saying it was 'basic organizational planning…after bringing people on board and undertaking yearly budgeting and planning exercises.' Meta CEO Mark Zuckerberg's push to get ahead in the AI race has sparked serious talent wars. He's personally called top researchers and engineers to offer them pay packages worth nine figures, and acquired either other startups or their leadership. Analysts have warned that the rise of stock-based compensation costs could threaten shareholder returns.

Meta Freezes AI Hiring as Surging Costs Raise Concerns, Report Says
Meta Freezes AI Hiring as Surging Costs Raise Concerns, Report Says

Yahoo

time8 hours ago

  • Yahoo

Meta Freezes AI Hiring as Surging Costs Raise Concerns, Report Says

Meta Platforms (META) reportedly has frozen hiring in its high-profile artificial intelligence division as investors grow concerned about the unit's surging costs. According to The Wall Street Journal, the tech giant began the freeze last week amid a broader restructuring, and exceptions would require the approval of chief AI officer Alexandr Wang. Meta has hired 50-plus AI engineers and researchers for the four-team unit, and "prohibits current employees from moving across teams inside the division," the report said. Meta hired Scale AI CEO Wang in June to lead an AI "superintelligence group." The tech giant has been among the most aggressive in the sector in poaching engineers and researchers to staff up its AI division, reportedly offering nine-figure pay packages as well as using so-called "reverse acquihires," where it buys into a startup to get its leaders, as it did with Scale AI. The Journal said that some analysts are worried that Meta's stock-based compensation costs would threaten shareholder returns. Meta didn't immediately respond to an Investopedia request for comment. The tech firm's shares, which entered Thursday up 28% this year, are little changed in premarket trading. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

Yahoo

timea day ago

  • Yahoo

KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals

Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ -- KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors. The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy. "We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients." "KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry," said Bill Snider, Partner at BroadOak Capital Partners. "We are proud to continue our partnership as they enter their next phase of growth." Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis. About KROMATIDKROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval. About BroadOak Capital PartnersBroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit Media Contact:Amanda LadasGlobal Marketing ManagerKROMATIDaladas@ View original content to download multimedia: SOURCE KROMATID Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store